IBRX - Company ID 0001326110
The table below shows ImmunityBio, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.19M | $60.24M | $137.66M | $60.66M | $111.97M | $130.10M |
| Short-term investments | $175.69M | $197.57M | $16.00M | $931.00K | $18.40M | $87.88M |
| Receivables | $43.27M | $32.02M | $22.13M | $17.03M | $4.17M | $1.03M |
| Inventory | $547.00K | $6.70M | $6.64M | $8.44M | $1.96M | $1.81M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $452.95M |
| $329.50M |
| $208.13M |
| $109.16M |
| $163.15M |
| $242.83M |
| Property, plant & equipment | $112.78M | $129.60M | $133.00M | $135.27M | $139.28M | $141.96M |
| Goodwill | $910.00K | $910.00K | $910.00K | $910.00K | $910.00K | - |
| Total assets | $646.64M | $518.99M | $402.08M | $303.76M | $364.57M | $444.32M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $67.95M | $57.13M | $50.64M | $49.20M | $60.96M | $62.11M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.52B | $1.04B | $971.89M | $894.24M | $1.11B | $1.14B |
| Retained earnings | -$4.36B | -$3.66B | -$3.60B | -$3.50B | -$3.32B | -$3.23B |
| Total equity | -$870.01M | -$524.32M | -$570.75M | -$591.43M | -$745.15M | -$698.39M |